Day: March 30, 2023

WISeKey International Holding Ltd. Announces Effectiveness of Registration Statement Relating to Proposed Partial Spin-off of its Semiconductor Business Geneva, Switzerland – March 30, 2023 – Ad-Hoc announcement pursuant to Art. 53 of SIX Listing Rules – WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, AI and IoT company, announced today that the U.S. Securities and Exchange Commission (the “SEC”) has declared effective the Registration Statement on Form F-1 filed by its wholly-owned subsidiary, SEALSQ Corp (“SEALSQ”). As previously announced, the Registration Statement on Form F-1 was filed to effect a partial spin-off of SEALSQ, which currently acts as the holding company for our semiconductor business. WISeKey proposes to distribute 20% of SEALSQ’s outstanding Ordinary...

INSIDE INFORMATIONCombination of ATO with copper salts will allow BioSenic to work towards reducing the dosage of ATO in future trials overall and maintain efficacyMont-Saint-Guibert, Belgium, March 30, 2023, 7am CET – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in severe autoimmune/inflammatory diseases and cellular repair, today announces that data providing additional details about the mechanism of action of its lead API arsenic trioxide (ATO) to prevent autoimmune diseases has now been published in a peer-reviewed paper. The article entitled “Optimal combination of arsenic trioxide and copper ions to prevent autoimmunity in a murine HOCl-induced model of systemic sclerosis” also details an original ATO formula to maximize efficacy in fighting autoimmunity and reducing side effects. The...

Saint Herblain (France), March 30, 2023 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today it will present on its single-shot chikungunya vaccine candidate, VLA1553, and host a roundtable on Zika vaccines next week at the 23rd World Vaccine Congress in Washington, D.C. On April 4, 2023, at 11.40am EDT, Valneva’s Chief Medical Officer, Juan Carlos Jaramillo, MD, will host a roundtable discussion on the opportunities and challenges for a Zika vaccine. Valneva successfully developed an inactivated whole-virus Zika vaccine candidate though Phase 1 prior to the COVID-19 pandemic and is currently evaluating potential re-entry into clinical development later this year or early next year. In addition, on April 5, 2023, at 9.40am EDT, Susanne Eder-Lingelbach, Vice President, Clinical Development at Valneva,...

Tortola, British Virgin Islands, March 30, 2023 (GLOBE NEWSWIRE) — Tortola, British Virgin Islands – March 30, 2023: SEALSQ Corp (“SEALSQ”), a company that focuses on developing and selling Semiconductors, PKI and Post-Quantum technology hardware and software products and a wholly-owned subsidiary of WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a Swiss based leading global cybersecurity, AI and IoT company, today announced that the U.S. Securities and Exchange Commission (the “SEC”) has declared effective its Registration Statement on Form F-1. As previously announced by WISeKey, the Registration Statement on Form F-1 was filed to effect a partial spin-off of SEALSQ from WISeKey, which currently acts as the holding company for its semiconductor business. WISeKey proposes to distribute 20% of SEALSQ’s...

Trondheim, 30 March 2023: NORBIT today announces that it has published its Annual Report for 2022, which also includes the Sustainability Report and the Corporate Governance Report, which the board of directors approved on 29 March 2023. “Our ability to develop and grow continued to be demonstrated in 2022. We delivered close to 50 per cent growth in revenues and improved profitability, driven by strong performance across all our business segments. We are on-track to reach our ambition of delivering NOK 1.5 billion in revenues and an EBITDA margin of 25 per cent in 2024. Since 2010, revenues have on average grown by 31 per cent annually and we have improved our profitability, laying the foundation for long-term value creation,” says Per Jørgen Weisethaunet, CEO of NORBIT. The report is attached to this notice and is also available...

LUXEMBOURG, March 30, 2023 (GLOBE NEWSWIRE) — Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) announced today that its Brazilian subsidiary Confab Industrial S.A., together with its affiliates Ternium Investments and Ternium Argentina, all of which compose the T/T group within Usiminas control group, have entered into a share purchase agreement to acquire from Nippon Steel Corporation, Mitsubishi and MetalOne (the “NSC group”), pro rata to their current participations in the T/T group, 68.7 million ordinary shares of Usinas Siderúrgicas de Minas Gerais S.A. – USIMINAS (“Usiminas”) at a price of BRL10 per ordinary share. Pursuant to the transaction, Tenaris would pay BRL 110 million (approximately USD21 million) in cash for 11.0 million ordinary shares, increasing its participation in the Usiminas control group to 9.8%. The...

REDWOOD CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $30.00 per share. The gross proceeds to Biomea from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $150.0 million. In addition, Biomea has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the public offering price less underwriting discounts and...

Revenues increase 26% on the strength of waste treatment contracts with multinational corporate clientsSingapore & New York, NY, March 29, 2023 (GLOBE NEWSWIRE) — Environmental Solutions Group Holdings Limited (“ESGL”) today announced the filing of an amendment to the registration statement on Form F-4 (the “Registration Statement”) filed by ESGL Holdings Limited (“PubCo”) with the U.S. Securities and Exchange Commission (“SEC”), which includes the financial results of ESGL for the fiscal years ended December 31, 2022 and 2021. ESGL, through its operating entity in Singapore, Environmental Solutions (Asia) Pte. Ltd. (“ESA”), is a sustainable waste solutions provider whose mission is to recycle industrial waste into circular products using innovative technologies and renewable energy. On November 30, 2022, Genesis Unicorn...

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 30, 2023, to provide a corporate update and discuss the Company’s financial results for the fourth quarter and full year ended December 31, 2022. A live audio webcast of the call be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. About Avadel Pharmaceuticals plcAvadel Pharmaceuticals plc...

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (“Avadel”) (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the pricing of an underwritten public offering of 10,000,001 of its ordinary shares, nominal value $0.01 per share (“Ordinary Shares”) in the form of American Depositary Shares (“ADSs”) and of 4,705,882 Series B Non-Voting Convertible Preferred Shares, convertible into Ordinary Shares on a one-for-one basis (the “Preferred Shares,” together with the ADSs, the “Shares”). Each ADS represents the right to receive one Ordinary Share. All of the Shares are being offered by Avadel. The public offering price of each ADS is $8.50 and the public offering price of each Preferred Share is $8.50. In connection with the public offering, Avadel...